Fig. 4
From: Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Strategies for overcoming immunotherapy resistance in GBM. Multiple combination strategies, including SOC combined with immunotherapies, ICIs combined with other types of immunotherapies (e.g., CAR-T-cell therapies, cancer vaccines, and OV therapies), and myeloid cell-targeted therapies combined with ICIs, have been developed to overcome immunotherapy resistance in GBM. APC antigen-presenting cell, CAR chimeric antigen receptor, GBM glioblastoma, ICIs immune checkpoint inhibitors, OV oncolytic virus, RT radiotherapy, SOC standard of care, TMZ temozolomide
